Can Glutamine Help Prevent Chemotherapy-Related Diarrhea in Colorectal Cancer Patients? A Patient-Friendly Guide

Table of Contents

• Key Points
• Why This Research Matters
• Why Diarrhea Is a Serious Problem During Cancer Treatment
• What Is Glutamine?
• How the Research Was Conducted
• Key Findings: What the Researchers Discovered
• Who Benefits Most? A Closer Look at Subgroups
• How Glutamine Works in the Body
• What This Means for Patients
• Study Limitations: What This Research Couldn't Prove
• Practical Recommendations for Patients
• Frequently Asked Questions
• Source Information

Key Points

• Glutamine reduced diarrhea risk by 28% in colorectal cancer patients on chemotherapy or chemoradiotherapy, based on 5 RCTs involving 311 patients.
• Benefit was strongest with chemotherapy alone, showing a 35% risk reduction, but not significant with chemoradiotherapy.
• Patients on glutamine had better intestinal absorption (higher D-xylose) and less inflammation (lower C-reactive protein).
• Evidence was rated low certainty due to small sample size, varying glutamine doses, and inconsistent diarrhea definitions.
• Always consult your oncology team before taking glutamine; it is an addition, not a replacement, for standard care.

Why This Research Matters

Colorectal cancer is a major global health concern, affecting hundreds of thousands of people each year. In fact, researchers project that approximately 3.3 million new cases will emerge by 2040. It is currently considered one of the most common malignant tumors of the digestive system, and both its incidence and death rate have been rising year after year.

Radiation therapy and chemotherapy are key treatments for this disease. They work by slowing or stopping the spread of cancer cells. But these powerful treatments come with a significant downside: they can damage the intestinal mucosal structure (the protective lining of the gut), increase intestinal permeability (a "leaky gut" effect), and interfere with the normal turnover of cells lining the intestine. This damage reduces the intestine's ability to absorb nutrients and water, and the most common and distressing result is diarrhea.

This study, published in BMC Gastroenterology in 2025, set out to answer a simple but important question: can giving patients glutamine—an amino acid that serves as fuel for intestinal cells—help prevent or reduce this chemotherapy-induced diarrhea?

Why Diarrhea Is a Serious Problem During Cancer Treatment

Diarrhea during cancer treatment is not just an inconvenience. It can have serious consequences:

• Reduced quality of life: Frequent trips to the bathroom, urgency, cramping, and dehydration can make daily life miserable.
• Poor nutritional status: When food and water pass through the digestive system too quickly, the body fails to absorb the nutrients it needs.
• Decreased immune function: Nutrient loss and dehydration weaken the body's defenses at a time when they matter most.
• Treatment disruptions: Severe diarrhea often forces doctors to reduce chemotherapy doses, delay treatment cycles, or stop treatment entirely—which can directly affect how well the cancer treatment works.

This is why preventing diarrhea is so important. Maintaining intestinal function during cancer treatment isn't just about comfort; it can influence whether a patient is able to complete their full course of therapy.

What Is Glutamine?

Glutamine is a non-essential amino acid, meaning the human body can normally produce it on its own. However, under stressful conditions like cancer treatment, the body's demand for glutamine may outstrip its supply. Glutamine is an important energy source for fast-dividing cells—especially the cells that line the intestine (enterocytes) and immune cells.

Glutamine plays several crucial roles:

• Maintaining the integrity of the intestinal mucosal barrier (the gut's first line of defense)
• Supporting immune system function
• Promoting the synthesis of heat shock proteins and antioxidants (such as glutathione) that protect cells from damage
• Enhancing tight junction proteins (such as claudin-1) that keep intestinal cells tightly sealed together

Earlier animal studies showed that glutamine could reduce the severity of colitis (inflammation of the colon) caused by chemoradiotherapy, ease intestinal mucosal damage, and improve the atrophy (shrinking) of intestinal lining cells. This meta-analysis was designed to see whether those benefits hold up in human patients with colorectal cancer.

How the Research Was Conducted

The researchers followed strict international guidelines for conducting meta-analyses, known as the PRISMA 2020 (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. The study was also pre-registered in an international database (registration number: INPLASY202490057), which helps ensure transparency and accountability.

Search Strategy

Three researchers conducted a comprehensive electronic search of five major medical databases—PubMed, Embase, Cochrane Library, CNKI, and Wanfang—covering all studies published up to August 1, 2024. They looked specifically for randomized controlled trials (RCTs), the gold standard of medical evidence, that tested glutamine for preventing diarrhea in colorectal cancer patients.

Study Selection

The initial search retrieved 260 articles. After removing 71 duplicate records, 143 studies were excluded based on a review of titles and abstracts. The remaining 46 studies underwent full-text review. Ultimately, only 5 randomized controlled trials met all the inclusion criteria.

To be included, a study had to:

1. Involve patients with colon or colorectal cancer;
2. Use glutamine during chemotherapy or chemoradiotherapy (radiation plus chemotherapy);
3. Compare glutamine against a placebo or no treatment (blank control);
4. Report diarrhea as an outcome measure.

Excluded were animal studies, abstracts, reviews, pharmacological reports, and any studies with insufficient data or inconsistent content.

Quality Assessment and Statistical Analysis

Two researchers independently assessed the quality of each trial using the Cochrane Reviewer Handbook 5.1.0 criteria. They used funnel plots and Egger's test (a statistical method) to check for publication bias—the tendency for positive results to get published while negative ones get shelved. The certainty of the evidence was graded using the GRADE system (Grading of Recommendations Assessment, Development, and Evaluation), which classifies evidence as high, moderate, low, or very low.

Key Findings: What the Researchers Discovered

All five trials were randomized controlled trials with a total of 311 patients. The study designs and patient characteristics are summarized in the table below.

Abbreviations: RCT = randomized controlled trial; 5-FU/FA = 5-fluorouracil/folinic acid (leucovorin); CapeOX = oxaliplatin plus capecitabine; CRP = C-reactive protein; IV = intravenous.

Glutamine doses varied across the studies, ranging from 10 to 30 g/day taken orally to 0.3–0.5 g/kg given intravenously.

The Main Result: A 28% Reduction in Diarrhea Risk

The headline finding: compared with control groups, patients who received glutamine had a significantly lower chance of developing diarrhea from their cancer treatment. The combined analysis showed a relative risk (RR) of 0.72 (95% confidence interval: 0.60–0.87; P < 0.01).

What does this mean in plain language? A relative risk of 0.72 means glutamine reduced the risk of diarrhea by 28% compared to the control group. In other words, if 100 patients in the control group developed diarrhea, only about 72 patients in the glutamine group would be expected to experience it. The confidence interval (0.60 to 0.87) tells us we can be reasonably confident the true effect lies between a 13% and a 40% risk reduction. The P-value of less than 0.01 means there is less than a 1% probability that this result was due to random chance.

The statistical heterogeneity among the studies was low to moderate (I² = 37%), meaning the studies were reasonably consistent in their findings—another mark in favor of the result being genuine.

Secondary Findings: Better Absorption and Less Inflammation

The meta-analysis also looked at two important biomarkers:

• D-xylose levels (a marker of intestinal absorption): D-xylose is a type of sugar that the body absorbs in the small intestine. Higher levels in the blood after drinking a D-xylose solution indicate better intestinal absorption. Patients in the glutamine group had significantly higher D-xylose levels (mean difference = 0.32, 95% CI: 0.14–0.51; P < 0.01; I² = 0%). The absence of heterogeneity (I² = 0%) means all studies pointed in the same direction with remarkable consistency.
• C-reactive protein (CRP, a marker of inflammation): CRP is a protein made by the liver that rises when there is inflammation somewhere in the body. Patients in the glutamine group had significantly lower CRP levels (mean difference = 0.52, 95% CI: 0.32–0.72; P < 0.01; I² = 0%), indicating less systemic inflammation.

These two findings are important because they provide biological evidence that glutamine is doing something real: helping the gut absorb nutrients better and cooling down treatment-related inflammation.

Sensitivity Analysis and Publication Bias

The researchers also ran a sensitivity analysis limited to the English-language studies. This analysis still showed a significant benefit: RR = 0.80 (95% CI: 0.65–0.98; P < 0.05; I² = 27%), a 20% reduction in diarrhea risk. Publication bias was assessed using both a funnel plot and Egger's test, and neither showed significant evidence of publication bias (P > 0.05). The quality of the included RCTs was rated as high.

Who Benefits Most? A Closer Look at Subgroups

Not all patients benefited equally. The researchers performed subgroup analyses to figure out who gets the most protection from glutamine.

Chemotherapy Alone vs. Chemoradiotherapy

Glutamine was more effective in patients receiving chemotherapy alone than in those undergoing combined chemotherapy plus radiation (chemoradiotherapy). For the chemotherapy-only group, the relative risk was 0.65 (95% CI: 0.43–0.98; P < 0.05; I² = 35%)—a 35% reduction in diarrhea risk. By contrast, patients receiving chemoradiotherapy (often rectal cancer patients) did not show a statistically significant benefit.

Why the difference? Radiation therapy damages the gut through more complex pathways—including oxidative stress, death of the cells lining the gut (crypt cell apoptosis), and chronic inflammation—that may be too severe for standard doses of glutamine to fully repair. In simple terms: chemotherapy damage may be within "repair range" for glutamine, but radiation adds a layer of injury that is harder to overcome.

Colorectal Cancer vs. Rectal Cancer

Looking at tumor location, glutamine significantly reduced diarrhea in the colorectal cancer subgroup (RR = 0.65, 95% CI: 0.44–0.97; P < 0.05; I² = 30%)—a group where patients typically receive chemotherapy alone. In contrast, no statistically significant benefit was found in the rectal cancer subgroup (P > 0.05), where patients typically receive chemoradiotherapy as standard neoadjuvant (pre-surgery) or definitive treatment.

The low heterogeneity (I² = 30%) in the colorectal subgroup suggests consistent results across studies, lending additional credibility to this finding.

Other Subgroups

No statistically significant differences were found when comparing:

• Administration route: intravenous injection vs. oral administration
• Geographic population: Western vs. Eastern populations

How Glutamine Works in the Body

Chemotherapy and radiation disrupt the gut's normal balance through several mechanisms. They inhibit thymidylate synthase, an enzyme needed for DNA synthesis in mucosal cells; impair DNA repair; and trigger excessive production of nitric oxide, causing the intestinal villi (tiny finger-like projections that absorb nutrients) to shrink and the gut lining to become leaky. At the same time, activation of a signaling pathway called NF-κB ramps up production of pro-inflammatory molecules, including TNF-α and IL-6, which further damage the gut lining and allow bacteria to escape into the bloodstream.

Glutamine fights back on multiple fronts:

• It serves as a primary energy source for enterocytes, the cells that line the intestine, helping them survive and regenerate.
• It promotes the synthesis of heat shock proteins, which protect cells from stress.
• It boosts production of glutathione, a powerful antioxidant that neutralizes damaging free radicals.
• It enhances tight junction proteins (such as claudin-1), which seal the gaps between intestinal cells and keep the gut barrier intact.

The finding that D-xylose absorption improved and CRP levels dropped in the glutamine group fits perfectly with this biological story: better gut barrier function means better absorption and less inflammation leaking into the bloodstream.

What This Means for Patients

So what are the practical takeaways for someone facing colorectal cancer treatment?

First, glutamine shows genuine promise as a preventive tool. A 28% reduction in diarrhea risk is clinically meaningful. Diarrhea is one of the most common reasons for chemotherapy dose reductions and treatment delays. If glutamine can prevent even some of that diarrhea, it could help more patients complete their full treatment course on schedule, potentially improving long-term outcomes.

Second, the benefit appears strongest for colon/colorectal cancer patients receiving chemotherapy alone. If you are in this group, glutamine supplementation may be worth discussing with your oncology team. For rectal cancer patients receiving chemoradiation, the evidence is less clear, and glutamine should not be relied upon as the sole strategy.

Third, biomarkers back up the clinical findings. The improvements in D-xylose absorption and the reduction in CRP are objective evidence that glutamine is benefiting the gut, not just a placebo effect.

One important caveat: the certainty of evidence was rated as low, downgraded mainly because of the modest number of patients and variations in study methods. This means the results are encouraging but not definitive.

The researchers compared their findings to a broader 2020 meta-analysis that included many different cancer types and found only marginal benefits of glutamine on gastrointestinal toxicity (RR = 0.88, 95% CI: 0.76–1.02). The fact that this colorectal-focused analysis found a stronger effect (RR = 0.72) suggests that glutamine may work better for some cancers specifically and highlights why disease-specific research matters.

Study Limitations: What This Research Couldn't Prove

The authors were transparent about several limitations that patients should be aware of:

• Modest sample size: A total of 311 patients across 5 trials is relatively small for drawing firm conclusions.
• Variable glutamine dosing: Doses ranged from 10 to 30 g/day orally and 0.3 to 0.5 g/kg intravenously. This variation makes it hard to determine the optimal dose.
• Inconsistent diarrhea definitions: Studies didn't use a uniform system to grade diarrhea severity. Some defined it by stool frequency, others by stool consistency. The researchers specifically recommended that future studies adopt the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, which grades diarrhea objectively (Grade 1: fewer than 4 additional stools per day; Grade 2: 4–6 additional stools per day) and excludes infectious causes.
• Tumor classification issues: Some studies didn't clearly distinguish between colon and rectal cancer sublocations, and sample distribution across subgroups was uneven. This could have introduced confounding and may explain the null finding in the rectal cancer subgroup (a possible false-negative result).
• Potential publication bias: Although testing showed no significant publication bias, the authors noted that no eligible unpublished studies were found in ClinicalTrials.gov, so "file-drawer" effects (unpublished negative results) can't be fully ruled out.
• No pharmacogenetic analysis: The studies did not examine genes that regulate glutamine metabolism, so it's unknown whether certain patient subgroups might respond better or worse than others.
• Translational gap: Although the biomarkers (higher D-xylose, lower CRP) aligned with the clinical benefit, no study linked these changes directly to patient-reported outcomes like diarrhea severity or quality of life.
• Low certainty of evidence: The GRADE assessment rated the evidence for diarrhea as low, meaning future research could change these conclusions.

Practical Recommendations for Patients

Based on this study—and keeping in mind the low certainty of evidence—here are practical steps to consider:

1. Talk to your oncology team first. Never start any supplement, including glutamine, without discussing it with your cancer doctor. Some supplements can interfere with chemotherapy or radiation.
2. Ask about glutamine if you're receiving chemotherapy for colon/colorectal cancer. This is the group where the evidence of benefit is strongest (35% risk reduction). Ask whether oral glutamine supplements (typically 18–30 g/day in the studies) might be appropriate for your situation.
3. If you have rectal cancer receiving chemoradiotherapy, manage expectations. The evidence doesn't currently show a clear benefit in this group, though this might change with better-designed future studies.
4. Monitor diarrhea closely and report it promptly. Early intervention makes a difference. If you develop diarrhea, your care team may recommend oral rehydration solutions, anti-diarrheal medications, or dietary adjustments—and some of those measures can be used alongside glutamine.
5. Keep a stool diary. Track how many times you go to the bathroom per day and the consistency of your stools. This helps your team grade the severity and decide whether to continue or adjust treatment.
6. Stay alert for new research. The authors called for larger, high-quality trials with standardized definitions (using CTCAE 5.0) and clearer tumor classification. As new evidence emerges, recommendations may become stronger or more refined.
7. Do not use glutamine as a replacement for standard care. This study suggests glutamine is a helpful addition, not an alternative, to proven anti-diarrheal strategies or to your cancer treatment itself.

In conclusion, this meta-analysis found that glutamine supplementation is associated with a reduced incidence of diarrhea in colorectal cancer patients, with the most pronounced benefit in those receiving chemotherapy alone and in the colorectal cancer subgroup. The likely mechanisms involve improved intestinal integrity (reflected in higher D-xylose levels, a marker of better absorption) and reduced inflammation (reflected in lower C-reactive protein). While these results are encouraging, low certainty of evidence means further high-quality research is needed to validate the findings and determine optimal dosing strategies. If you're a colorectal cancer patient about to start chemotherapy, this is a topic worth raising with your doctor.

Frequently Asked Questions

What did this research find about glutamine and diarrhea during colorectal cancer treatment?

In a meta-analysis of 5 randomized controlled trials involving 311 patients, glutamine supplementation reduced the risk of diarrhea by 28% compared with control groups. Patients taking glutamine also showed better intestinal absorption and lower inflammation. However, the evidence was rated as low certainty, so larger studies are still needed.

Who benefited most from glutamine in this meta-analysis?

The benefit was strongest in patients receiving chemotherapy alone, with a 35% risk reduction. Patients with colon or colorectal cancer also showed significant benefit. In contrast, those receiving chemoradiotherapy, often rectal cancer patients, did not show a statistically significant benefit in this analysis.

What doses of glutamine were used in the studies?

Glutamine doses varied across the studies. Oral doses ranged from 10 to 30 grams per day, and intravenous doses ranged from 0.3 to 0.5 grams per kilogram. Because dosing varied, the researchers noted that the optimal dose could not be determined from this analysis.

Should I start taking glutamine before or during my cancer treatment?

Do not start any supplement, including glutamine, without discussing it with your oncology team first. This study suggests glutamine may help prevent diarrhea, especially if you receive chemotherapy for colon or colorectal cancer. However, the evidence is low certainty, and supplements can interfere with cancer treatment.

How does glutamine help reduce diarrhea during chemotherapy?

Glutamine serves as fuel for intestinal cells, supports the gut barrier, boosts antioxidants, and reduces inflammation. In this analysis, patients taking glutamine had higher D-xylose levels, indicating better nutrient absorption, and lower C-reactive protein, indicating less inflammation, which may explain the reduced diarrhea risk.

What are the limitations of this research on glutamine?

The meta-analysis included only 311 patients across 5 trials, which is a small sample. Studies used different glutamine doses and definitions of diarrhea. The certainty of evidence was rated as low, meaning future research could change the conclusions. The authors call for larger, higher-quality trials.

Does glutamine replace standard treatments for chemotherapy-induced diarrhea?

No. This study suggests glutamine is a helpful addition, not an alternative, to proven anti-diarrheal strategies or your cancer treatment itself. If you develop diarrhea, your care team may recommend rehydration solutions, anti-diarrheal medications, and dietary adjustments, which can be used alongside glutamine.

When should a colorectal cancer patient consider a second opinion about using glutamine for chemotherapy-related diarrhea?

A colorectal cancer patient receiving chemotherapy may consider a second opinion if their oncology team has not discussed glutamine for diarrhea prevention. In clinical trials, glutamine reduced diarrhea risk by 28%, and the benefit was stronger in patients receiving chemotherapy alone, with a 35% risk reduction. However, the evidence was rated as low certainty, so a specialist can help weigh potential benefits against uncertainties and whether it fits your treatment plan. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

This patient-friendly article is based on the following peer-reviewed research:

Original Title: "Glutamine prevents diarrhea in colorectal cancer patients undergoing chemotherapy or chemoradiotherapy: a meta-analysis"

Authors: Chen L, Wang D, Meng C, Sun H, Li R, Miao G, Liu P.

Journal: BMC Gastroenterology (2025) 25:697

DOI: https://doi.org/10.1186/s12876-025-04308-w

Study Registration: INPLASY (registration number: INPLASY202490057)

Funding: The authors declared no external funding for this study.

Conflicts of Interest: The authors declared no competing interests.

The original article is published under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. This patient summary is provided for educational purposes only and does not constitute medical advice. Always consult your healthcare provider before making any changes to your treatment or supplement regimen.